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Abstract 
Objective: The objective of this study is to examine the association between chocolate intake 
and the risk of future cardiovascular events. 
Methods:  We conducted a prospective study using data from the European Prospective 
Investigation into Cancer (EPIC)-Norfolk cohort. Habitual chocolate intake was quantified 
using the baseline food frequency questionnaire (1993-1997) and cardiovascular end points 
were ascertained up to March 2008.  A systematic review was performed to evaluate 
chocolate consumption and cardiovascular outcomes.  
Results: A total of 20,951 men and women were included in EPIC-Norfolk analysis (mean 
follow-up 11.3±2.8 years, median 11.9 years). The percentage of participants with coronary 
heart disease (CHD) in the highest and lowest quintile of chocolate consumption was 9.7% 
and 13.8% and the respective rates for stroke were 3.1% and 5.4%. The multivariate-adjusted 
hazard ratio (HR) for CHD was 0.88 (0.77-1.01) for those in the top quintile of chocolate 
consumption (16-99 g/day) versus non-consumers of chocolate intake. The corresponding HR 
for stroke and cardiovascular disease (CVD defined by the sum of CHD and stroke) were 0.77 
(0.62-0.97) and 0.86 (0.76-0.97). The propensity score matched estimates showed a similar 
trend. A total of 9 studies with 157,809 participants were included in the meta-analysis. 
Higher compared to lower chocolate consumption was associated with significantly lower 
CHD risk (5 studies; pooled RR 0.71 (0.56-0.92)), stroke (5 studies; pooled RR 0.79 (0.70-
0.87)), composite cardiovascular adverse outcome (2 studies; pooled RR 0.75 (0.54-1.05)) 
and cardiovascular mortality (3 studies; pooled RR 0.55 (0.36-0.83)).   
Conclusions: Cumulative evidence suggests that higher chocolate intake is associated with a 
lower risk of future cardiovascular events though residual confounding cannot be 
excluded.There does not appear to be any evidence to say that chocolate should be avoided in 
those who are concerned about cardiovascular risk. 
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Key Questions 
 
What is already known about this subject? 
 Chocolate consumption has been associated with a lower risk of cardiovascular 
disease, but studies have limitations with regard to participant selection and combined 
outcome measures. 
What does this study add? 
 We observed evidence that higher intake of chocolate may be associated with lower 
cardiovascular disease and mortality. 
 Our meta-analysis of eight studies found a lower risk of cardiovascular disease with 
chocolate consumption. 
How might this impact clinical practice? 
 Our study adds to the previously found inverse associations between chocolate intake 
and risk of future cardiovascular events. 
 There does not appear to be any evidence to say that chocolate should be avoided in 
those who are concerned about cardiovascular risk. 
5 
 
Introduction 
Chocolate is an important dietary source of flavonoid antioxidants, which are hypothesized to 
have a beneficial effect on endothelial function and protect against cardiovascular disease 
(CVD) [1]. Evidence from a range of small-scale intervention trials have reported that intake 
of chocolate resulted in increased high-density lipoprotein (HDL) cholesterol levels, 
decreased low-density lipoprotein (LDL) oxidation and improved endothelial function [2]. 
Large-scale intervention studies have not been performed and therefore the potential benefits 
of raising chocolate consumption on cardiovascular risk are unknown. However, some 
evidence on the potential beneficial effects of chocolate can be derived from observational 
studies.  
Many studies have evaluated the risk of cardiovascular outcomes with chocolate consumption 
[1-4]. One meta-analysis which attempted to quantify systematically the effect of high 
chocolate consumption was limited by inclusion of a heterogeneous spectrum of outcomes 
including diabetes and heart failure [3]. A more recent meta-analysis specifically evaluated 
the effects of flavonols (also found in other foods) and the risk of coronary heart disease 
(CHD) and found no significant association between flavonol intake and CHD [4]. Many 
cohort studies which examined the association between chocolate and CVD (defined by CHD 
and stroke in this study) are limited to sex-specific cohorts [5-9].   Two meta-analyses have 
been performed which pooled many of these studies and found reduced risk of incident stroke 
[7] and CVD [10] with higher chocolate consumption. However, these studies are limited 
because in one study only considered stroke while the other study pooled many different 
cardiovascular events into a single risk estimate. 
In order to evaluate the habitual chocolate consumption and the risk of cardiovascular events, 
we analyzed the data from the European Prospective Investigation into Cancer-Norfolk 
(EPIC-Norfolk), a large prospective population study in the United Kingdom and 
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incorporated the results from this observational study into the evidence available to date from 
the literature by conducting a systematic review and meta-analysis.   
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Methods 
EPIC-Norfolk Cohort study 
The European Prospective Investigation into Cancer (EPIC)-Norfolk is a prospective 
population study of over 25,000 men and women, resident in Norfolk, United Kingdom 
(99.6% white Caucasian). The study methods have been previously described previously in 
detail [11]. In brief, at the baseline survey between 1993 and 1997, participants completed a 
health and lifestyle questionnaire and provided information on physician-diagnosed chronic 
diseases such as cancer, myocardial infarction, stroke and diabetes mellitus. We identified 
cigarette smoking habit (never, former and current) [12] and a validated, self-reported 
physical activity measure (inactive, moderately inactive, moderately active, active) [13] and 
assessed reported intake of alcoholic drinks (where units (8 g alcohol)/week were categorized 
into: zero consumers, >0-7, >7-14, >14-21; >21-28; >28 units/week). At the baseline health 
examination (N=25,639), a trained nurse measured height, weight and blood pressure 
(Acutorr). Cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were 
measured in non-fasting blood samples as described previously [11]. Blood samples were 
stored at -80°C. Low-density lipoprotein (LDL) cholesterol was calculated by the Friedewald 
formula.  Data on lipids were available for 23,074 participants (90%) and for inflammation 
markers on minimally 18,643 participants (73%). 
 
Main exposure measure: chocolate consumption 
Dietary measurements were obtained by food frequency questionnaire (FFQ), which assessed 
overall diet in the past year from 24,782 participants (response rate 97%). Every food item or 
group of food items in the questionnaire had nine answer categories: never or less than once 
per month, 1-3 per month, once a week, 2-4 per week, 5-6 per week, once a day, 2-3 per day, 
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4-5 per day, 6+ per day.  This instrument and the way it is analysed using the Compositional 
Analyses from Frequency Estimates (CAFÉ), are described in detail elsewhere [14].   
Three questions from the FFQ were considered indicative of chocolate consumption, namely 
“Chocolates singles or squares” (average portion size of 8 g), “Chocolate snack bars, e.g. 
Mars, Crunchie” (average portion size of 50 g) and “Cocoa, hot chocolate (cup)” (average 
portion size of 12 g powder weight, the liquid to make up the beverage was hence not 
included).  Frequency categories were multiplied by the portion size to derive the amount of 
chocolate product eaten (g/day). The sum of the weights of these food items consumed, rather 
than their flavonoid or cocoa content, formed the measure of exposure. 
 
Clinical outcomes  
Participants admitted to hospital were identified using their unique National Health Service 
number by data linkage with ENCORE (East Norfolk Health Authority database). All 
participants were flagged for death certification at the UK Office of National Statistics, 
ascertaining vital status for the entire cohort. CHD was defined as ICD10 codes I20-25 
(which includes the spectrum of CHD including myocardial infarction, unstable angina and 
stable angina); stroke was defined as ICD10 codes I60-69 (which includes ischemic stroke, 
hemorrhagic stroke and stroke of undetermined cause). CVD was defined as the combination 
of CHD and stroke. A previous validation study in our cohort indicated high specificity for 
such case ascertainment [15]. We report data with follow-up up to 31 March 2008, an average 
of 11.3 years (2.8 standard deviation, median of 11.9 years). The study was approved by the 
Norwich District Health Authority Ethics Committee. All participants provided signed 
informed consent. 
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Statistical analysis 
Participants without a completed FFQ (n=857), with prevalent myocardial infarction or stroke 
(n=1102) and whose reported chocolate intake was more than 5 standard deviations above the 
median (i.e. 100 g/day) were excluded from the analyses (n=86). Leaving 23,638 participants 
eligible; we further excluded 2687 participant who missed data on one or more covariables 
(n=20,951). Baseline characteristics were calculated by quintiles of chocolate consumption. 
Since 4,195 participants (approximately 20%) reported zero chocolate intake, the lowest 
quintile corresponds to the non-users only and was used as the reference category in Cox 
proportional hazards model. Hazard ratios (HR) and corresponding 95% confidence intervals 
(95%CI) for the risk of future CHD, stroke or CVD were calculated using four models. 
Regression model 1 adjusted for sex and age. Regression model 2 additionally adjusted for 
lifestyle factors: smoking, physical activity, energy intake (per MJ/d) and alcohol intake 
(categorical). Regression model 3 adjusted for the variables in model 2 and possible 
mediators: body mass index, systolic blood pressure, LDL cholesterol, HDL cholesterol and 
prevalent diabetes.  In model 4 we additionally adjusted for C-reactive protein (CRP). 
Analyses were performed using SPSS version 17.0 (Chicago, Illinois, USA). 
 
Systematic review and meta-analysis 
To be eligible for inclusion in our review, studies had to report on the association between 
chocolate consumption and cardiovascular outcomes. We searched PubMed and EMBASE 
from inception until June 2013 using the terms described in Data Supplement 1, with no 
language limitations, and we checked bibliographies of included articles. In addition to our 
search of EMBASE (which already includes unpublished abstracts and conference reports) we 
also searched conference abstracts from the European Society of Cardiology Congresses from 
2005-2013 inclusive. A further search of ISI Web of Science was conducted in February 2014 
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to identify additional articles. Two reviewers independently screened abstracts and titles, and 
then obtained full-text versions of potentially relevant studies to confirm eligibility. Data 
extraction of included studies was performed by CSK as well as JKY, and checked by YKL. 
Study validity was evaluated based on ascertainment of chocolate consumption and 
cardiovascular outcomes as well as steps taken to reduce confounding in the primary studies. 
We pooled data using the inverse variance method and random effects model in RevMan 5.2 
software (Nordic Cochrane Center, Copenhagen, Denmark). For these comparisons, we used 
the multivariable adjusted measures of association (hazard ratios, relative risks or odds ratios) 
for the highest category of chocolate consumption versus the lowest category of consumption. 
Heterogeneity was estimated using I2, and we considered a value greater than 50% to 
demonstrate substantial heterogeneity [16]. We planned to evaluate publication bias through 
asymmetry testing if there were >10 studies in the dataset, and no evidence of significant 
heterogeneity [17].  
 
Sensitivity Analyses 
We performed additional analysis to determine if a similar direction of effect was observed 
using propensity score matching on the pre-specified covariates of models 1, 2 and 3. 
Propensity score matching were performed in STATA using the teffects psmatch function 
which estimates treatment effects from observational data [18].  The results of the propensity 
score analysis was used as sensitivity analysis for the meta-analysis.  We conducted additional 
analysis excluding the Djousse study because it was a cross-sectional study. 
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Results 
EPIC-Norfolk cohort 
A complete dataset on relevant baseline characteristics were available for 20,951 study 
participants; 9,214 men and 11,737 women (n=16,162 when restricted to participants with 
CRP data). Mean follow-up was 11.9 ± 2.8 years, total person year 236,942 years. A total of 
3,013 (14.4%) people experienced a fatal or non-fatal CHD event, stroke or both, referred to 
as CVD. Among these participants with CVD events, 2,434 (11.6%) had a CHD event and 
848 (4.0%) had a stroke event.  When analyses were limited to people with available CRP at 
baseline, a total of 2,207 (13.7%) study participants experienced a CVD event while 1,754 
(10.9%) and 648 (4.0%) had a CHD event and/or stroke event, respectively.  
 
Chocolate consumption in the EPIC-Norfolk cohort 
The median daily chocolate consumption was 4.6 g/day (interquartile range 0.6 to 12.0); 
among consumers only, median chocolate intake was 7.0 g/day (interquartile range 3.5 to 
15.5). Higher chocolate consumption was associated with trends towards a beneficial 
cardiovascular risk factor profile including lower age, lower body mass index, lower waist/hip 
ratio, lower systolic blood pressure, lower levels of apolipoprotein B (apoB) and CRP, a 
lower prevalence of diabetes mellitus and more physical inactivity (Table 1). In contrast, 
higher chocolate consumption was more prevalent among men and among current smokers. 
Higher chocolate intake was associated with a higher energy intake, with lower contributions 
from protein and alcohol sources and higher contribution from fat and carbohydrates.  
 
Chocolate consumption and risk of cardiovascular disease in EPIC-Norfolk 
Higher chocolate intake was associated with a statistically significant lower risk of CVD, with 
stronger associations for CVD mortality than for total CVD (hospitalization or mortality) 
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(Table 2).  HRs attenuated after adjustment, but remained borderline significant for total 
CVD (HR 0.89 (95% CI 0.79-1.00)) and CVD mortality (HR 0.75 (95%CI 0.62-0.92)). 
Adjustment for CRP minimally changed the effect estimates.  A significant dose-response 
association was present for both total incidence and CVD mortality. We assessed the 
proportionality assumption graphically and the results suggest that proportional hazards were 
maintained with time. 
 
Higher chocolate consumption was associated with a lower risk of hospitalization or mortality 
due to CHD in crude and minimally adjusted models (Table 3).  This association was 
attenuated after adjustment for a range of cardiovascular risk factors and after additional 
adjustment for a set of dietary parameters (HR 0.91, 95%CI 0.80-1.04). In the smaller sample 
of participants with CRP data, we observed a significant association with 18% lower risk in 
quintile 5 versus quintile 1 (95%CI 0.70-0.97). Participants with a high chocolate intake also 
had a lower risk of stroke. The sex- and age- adjusted HR was 0.77 (95%CI 0.62-0.96) for top 
versus bottom quintile of chocolate consumption (Table 3). This association remained 
statistically significant upon adjustment for smoking, physical activity and dietary variables. 
Additional adjustment for mediators did not materially change the estimate (HR 0.78, 95%CI 
0.63-0.98). Analyses using mortality as outcome rather than combined mortality and 
hospitalizations, showed lower risk estimates for CVD, CHD and stroke, although the number 
of events were substantially lower and therefore the confidence intervals became wider. 
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Propensity score matched analysis for chocolate consumption and risk of cardiovascular 
disease 
The baseline characteristics of the unmatched and propensity matched cohorts are shown in  
Appendix Table 1. A Love plot was used to examine the standardized difference in 
covariates before and after propensity score adjustment (Appendix Figure 1). The risk of 
CHD and stroke by quintiles of chocolate intake considering various levels of adjustments 
and propensity score matching are shown in Appendix Table 2. After propensity score 
matching, a trend for benefit with chocolate consumption was apparent for both CHD and 
stroke, but with lower sample sizes and wider confidence intervals they were not statistically 
significant.  
 
Systematic Review and Meta-Analysis  
Search results and studies of chocolate and cardiovascular disease 
We screened 392 titles and abstracts and identified 8 studies [5-9,19-21] that met eligibility 
criteria (Appendix Figure 2). Including the EPIC-Norfolk study, there were a total of 9 
studies with 157,809 participants included in the meta-analysis. These studies included 7 
cohort studies, 1 post-hoc analysis of a randomized trial and 1 cross-sectional study and the 
follow up duration of the cohort studies ranged from 8 to 16 years (Table 4Table 4). Two 
studies were conducted in the United States and one study was conducted in Australia but the 
remainder were conducted in Europe (United Kingdom, Netherlands, Germany and Sweden). 
Three studies included both men and women but the remainder were sex specific (two studies 
of men and two studies of women). The mean age of the participants in the included studies 
ranged from 49 to 79 years. 
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Bias assessment for studies of chocolate and cardiovascular disease 
Different methods for evaluating and ascertaining chocolate consumption and cardiovascular 
outcomes were used across the studies (Appendix Table 3). One study used patient 
interviews to ascertain chocolate consumption but the remaining studies used questionnaires. 
The majority of studies used ICD codes to ascertain cardiovascular diagnoses.  Five of the 
studies used linkage of data to mortality registry/records in order to ascertain mortality. All 
the included studies were able to use a variety of adjustments to account for the effect of 
confounders; for the meta-analysis, we used data from Model 2 of EPIC-Norfolk. While a key 
cardiovascular risk factor such as body mass index was adjusted for in seven studies, other 
important risk factors such as cholesterol were only considered in two studies (Appendix 
Table 4). We considered the cross-sectional study to have lower validity due to the inability 
to draw a temporal relationship between chocolate use and adverse cardiovascular outcomes. 
 
Chocolate consumption and risk of cardiovascular events 
Overall, chocolate consumption was significantly associated with lower risk of CHD across 5 
studies, (pooled RR 0.71 95% CI 0.56-0.92, I2=61%) (Figure 1). The risk of CHD mortality 
from one study showed no significant difference with and without chocolate consumption 
(RR 0.98 95% CI 0.88-1.10). For risk of stroke with chocolate consumption there was 
significantly lower risk of both stroke incidence (pooled RR 0.79 95% CI 0.70-0.87, I2=0%, 5 
studies) (Figure 1) and mortality (RR 0.85 95% CI 0.74-0.98, 1 study). There was a 
significant lower risk of any cardiovascular event (pooled RR 0.75 95% CI 0.54-1.05, 
I2=70%, 2 studies) and cardiovascular mortality (pooled RR 0.55 95% CI 0.36-0.83, I2=67%, 
3 studies) (Figure 2). The propensity matched results were incorporated in the meta-analysis 
and this continued to show a significant association between chocolate consumption and 
reduction in CHD (pooled RR 0.72, 95% CI 0.55-0.93, I2=63, 5 studies) and stroke (pooled 
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RR 0.78, 95% CI 0.70-0.88, I2=0%, 5 studies) (Figure 3).  Publication bias was not assessed 
because there were fewer than 10 studies included in the analysis. 
We conducted additional analysis excluding the Djousse study because it was a cross-
sectional study.  The lower risk associated with chocolate and CHD was slightly less after 
exclusion of this study but still remained statistically significant (RR 0.84 95% CI 0.75-0.95 
vs. 0.79 95% CI 0.70-0.87) (Data not shown). 
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Discussion 
In this large prospective population study, higher intake of chocolate up to 100 g/day was 
associated with a lower risk of CVD and stroke, with stronger associations for mortality than 
total incidence. We have built on the findings of the previous meta-analysis [7,10] by 
including this current study in an updated meta-analysis.  The reviews by Larsson et al [7] 
only considered stroke as an outcome while the review by Zhang et al [10] considered CVD.  
The current review includes stroke, stroke mortality, CHD and CHD mortality separately.  In 
addition, we included the EPIC-Norfolk cohort which is a Caucasian population. Our results 
indicate that chocolate consumption was associated with a lower risk of CVD.  
 
A number of issues have to be taken into account when interpreting the results of the present 
study. Although FFQs are well-established methods to quantify dietary information in large-
scale population studies, they have limitations. Importantly, recall bias as well as 
underreporting, particularly among women and participants who are obese [22]. 
Underreporting is selective, and includes sweets and snacks. It is possible that lower CVD 
rates among people who report consuming more chocolate might be due to differential 
underreporting of chocolate intake in those with potentially greater CVD risk such as the 
obese and physically inactive. It has been suggested that dark chocolate may have more 
beneficial effects than milk chocolate [23]. Milk chocolate is more frequently consumed than 
dark chocolate in this cohort [unpublished results]; however, we still observed a reduced risk 
of CVD.  This may indicate that not only flavonoids, but also other compounds -possibly 
related to milk constituents such as calcium and fatty acids- may form an explanation of the 
observed association. In addition, the whole dietary pattern may be of relevance, giving 
concern for unmeasured confounding.  Therefore, this observational study cannot provide 
evidence on the potential causality of the observed association.  
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We used the Food Frequency Questionnaire (FFQ) to assess chocolate intake and this 
measure of dietary assessment method has been validated in the EPIC-Norfolk cohort [24].  
While the FFQ is prone to recall bias and requires the participant to 'average out' over a long 
period of time, this method has the advantage that it covers a longer time-frame than other 
methods such as 7-day diet diary (7dDD) and 24h-Diet Recall.  Chocolate consumption might 
be a more episodically consumed food for a proportion of the participants and this could have 
miss-classified the participant as a non-consumer or a high consumer depending in which 
week the 7dDD or day of 24h-Diet Recall would have been completed. 
 
It is possible that part of the observed association could be explained by reverse causality in 
that people with a higher risk profile, including those with obesity, diabetes mellitus, or 
prevalent CVD, eat less chocolate-containing foods than people who have a perceived healthy 
risk profile. However, we excluded people who reported prevalent CVD at the baseline health 
questionnaire, and analyses were adjusted for diabetes mellitus. We observed that the 
reference group (non-chocolate consumers) had the highest mean BMI, highest median CRP, 
highest proportion of participants with diabetes, highest levels of inactivity and lowest fat 
intake compared to the other quintiles of chocolate consumers.  Alternatively it may be that 
higher chocolate consumers have other behaviours that are beneficial for cardiovascular 
health.  Participants with a higher energy intake are also likely to have a higher energy 
expenditure due to physical activity. They are hence more likely to consume more foods, 
including chocolate containing foods, which may explain part of the observed associations, 
although stratified analyses suggested that the association found was homogeneous across 
levels of physical activity. In addition to multivariable adjustment, we conducted stratified 
analyses and propensity score matching for baseline differences.  Nevertheless we cannot 
exclude residual confounding from these or other unmeasured factors.  The consumption of 
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chocolate as well as its influence on cardiovascular risk may be different depending on 
ethnicity of participants.  External validity of our results may be limited to Caucasians.   
 
Our results are somewhat surprising since the expectation was that benefits of chocolate 
consumption would be mainly associated with dark chocolate rather than the commercially 
available products generally used in a British population which are high in sugar content and 
fat.    One study has shown reduced incidence of diabetes among men and women with 
chocolate intake [25], and other studies have shown that chocolate consumption increases 
body weight [26,27]. This may suggest that there is a balance between benefit and risk with 
chocolate intake which is dependent on the risk profile of the individual including baseline 
weight and dose of chocolate intake.   
 
We did not include heart failure as an outcome for the current analysis for a few reasons.  The 
pathophysiology of CHD and stroke which relates to atherosclerosis differs from that of heart 
failure.  The physiological changes in heart failure are largely driven by neuroendocrine 
dysregulation and renin-angiotensin-aldosterone system activation.  The mechanism by which 
chocolate might impact on these pathways may differ.  In addition, the risk factors and 
confounders in heart failure differ from those in the cardiovascular disease analysis. 
 
This analysis included clinical biomarkers and anthropometry measured by trained staff.  
Adjustment for these variables attenuated the association between chocolate consumption and 
risk of CVD, CHD and stroke, but particularly in case of stroke and fatal CVD, associations 
remained significant.  CRP was available for a subcohort, in which we observed a better 
cardiovascular risk profile; however, we observed that CRP did not modify the association 
between chocolate and CVD, CHD or stroke.  Pathways other than anti-inflammatory 
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markers, such as blood pressure, might be a more likely mechanism to explain the observed 
association between chocolate and CVD/stroke. 
 
Bias may also affect the systematic review if the original studies made post-hoc decisions on 
particular outcomes or categories for analysis based on nature of the findings. The primary 
studies collected data using different categories of chocolate consumption (e.g. frequent vs. 
rare, different quintiles or quartiles) and it seemed that some of the studies made post-hoc 
decisions on what the cut-offs were in defining categories for analysis (including pooling 
certain categories while excluding others). This raises the possibility of bias from selective 
outcome and analysis reporting where categorical cut-offs could have been chosen based on 
statistical significance of findings.  Nevertheless, the cumulative evidence reported in this 
study suggests that high chocolate consumption may be associated with cardiovascular 
benefit.   
 
Future research is still needed to explore the association between chocolate and CVD.  
Studies are needed to better understand the biological mechanism by which chocolate and 
flavonoids reduce the risk of CVD.  It is also possible that some individuals will not benefit 
from increased chocolate consumption such as those who are overweight or diabetic. More 
research is needed to identify individuals who would benefit the most.   
 
In conclusion, our findings support the previously reported association between habitual 
chocolate intake and a lower risk of CHD events in the large EPIC-Norfolk prospective 
population study and we have further set this in context with consistent results seen in meta-
analysis of current evidence.  While randomized controlled trials of chocolate and 
cardiovascular endpoints could be conducted, feasibility is uncertain. For the time being, 
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within the general context of existing recommendations for behaviours conducive to 
cardiovascular health, there does not appear to be evidence that chocolate should be avoided 
in terms of impact on cardiovascular risk. 
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Figure 1: Meta-analysis risk of the association between chocolate consumption and risk of 
coronary heart disease and stroke. 
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Figure 2: Meta-analysis of chocolate consumption and risk of cardiovascular disease 
(composite). 
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Figure 3: Meta-analysis risk of coronary heart disease and stroke with chocolate consumption 
using propensity matched cohort. 
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Table 1: Baseline cardiovascular risk factors by quintiles of chocolate intake in 20,951 men and women of EPIC-Norfolk. 1 
Quintiles of daily chocolate intake Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5 P Total 
Range (g/d) 0 0.6-3.5 4.1-7.0 7.2-15.5 15.6-98.8   
Median (interquartile range) (g/d)        
Chocolate intake 0 1.1 (0.6,3.4) 4.6 (4.1,6.3) 9.2 (8.1,12.0) 24.9 (22.1,39.5)   
Chocolate singles 
Chocolate bars 
Chocolate beverage 
0 
0 
0 
0.6 (0.0,1.1) 
0.0 (0.0,0.0) 
0.0 (0.0,0.0) 
0.6 (0.6,1.1) 
3.5 (3.5,3.5) 
0.0 (0.0,0.8) 
1.1 (0.6,3.4) 
7.0 (0.0,7.0) 
0.8 (0.0,5.2) 
1.1 (0.6,3.4) 
21.5 (21.5,21.5) 
0.0 (0.0,5.2)   
N 4195 4437 4035 4106 4178   20,951 
        
Sex, men 44.1 (1852) 43.4 (1927) 40.8 (1648) 43.5 (1786) 47.9 (2001) < 0.001 44.0 (9214) 
Age, years 61 ± 9 60 ± 9 58 ± 9 59 ± 9 57 ± 9 < 0.001 59 ± 9 
Body mass index, kg/m2 26.3 ± 4.1 26.1 ± 3.8 26.3 ± 3.7 26.2 ± 3.8 26.0 ± 3.7 < 0.001 26.2 ± 3.8 
Waist/hip ratio* 0.86 ± 0.09 0.85 ± 0.09 0.84 ± 0.09 0.85 ± 0.09 0.85 ± 0.09 < 0.001 0.85 ± 0.09 
Smoking   - current 10.5 (440) 10.7 (473) 11.4 (459) 11.4 (469) 13.0 (543) < 0.001 11.4 (2384) 
                  - previous 44.0 (1847) 43.1 (1914) 40.1 (1618) 40.9 (1678) 38.5 (1610)  41.4 (8667) 
                  - never 45.5 (1908) 46.2 (2050) 48.5 (1958) 47.7 (1959) 48.5 (2025)  47.3 (9900) 
Diabetes mellitus 4.6 (193) 1.6 (73) 0.9 (38) 0.9 (38) 0.7 (29) < 0.001 1.8 (371) 
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Systolic blood pressure, mmHg 137 ± 19 136 ± 18 134 ± 18 134 ± 18 135 ± 17 < 0.001 135 ± 18 
Diastolic blood pressure, mmHg 83 ± 11 83 ± 11 82 ± 11 82 ± 11 82 ± 11 0.010 82 ± 11 
Total cholesterol, mmol/l 6.2 ± 1.1 6.2 ± 1.1 6.1 ± 1.1 6.1 ± 1.1 6.1 ± 1.1 0.001 6.1 ± 1.1 
LDL-cholesterol, mmol/l 4.0 ± 1.0 4.0 ± 1.0 3.9 ± 1.0 4.0 ± 1.0 3.9 ± 1.0 0.07 4.0 ± 1.0 
HDL-cholesterol, mmol/l 1.43 ± 0.43 1.43 ± 0.42 1.44 ± 0.42 1.43 ± 0.41 1.40 ± 0.41 < 0.001 1.43 ± 0.42 
Triglycerides, mmol/l 1.5 (1.1-2.2) 1.5 (1.1-2.1) 1.5 (1.0-2.1) 1.5 (1.1-2.1) 1.5 (1.1-2.1) 0.20 1.5 (1.1-2.1) 
Apolipoprotein AI, mg/dl* 156 ± 35 157 ± 35 157 ± 35 156 ± 34 155 ± 36 0.29 156 ± 35 
Apolipoprotein B, mg/dl* 97 ± 26 97 ± 25 96 ± 25 96 ± 26 94 ± 25 0.001 96 ± 26 
C-reactive protein, mg/l* 1.6 (0.8-3.2) 1.5 (0.7-3.2) 1.5 (0.7-3.2) 1.4 (0.7-3.1) 1.4 (0.7-2.9) < 0.001 1.5 (0.7-3.1) 
Physical activity  - Inactive 32.7 (1373) 28.6 (1267) 26.9 (1084) 27.6 (1134) 27.2 (1138) < 0.001 28.6 (5996) 
                             - Moderately inactive 27.5 (1153) 30.2 (1340) 29.4 (1188) 30.2 (1241) 28.1 (1174)  29.1 (6096) 
                             - Moderately active 21.8 (914) 23.7 (1051) 24.1 (971) 22.8 (936) 24.3 (1015)  23.3 (4887) 
                             - Active 18.0 (755) 17.6 (779) 19.6 (792) 19.4 (795) 20.4 (851)  19.0 (3972) 
Energy intake by FFQ, kJ/day 7754 ± 2264 8043 ± 2233 8359 ± 2311 8934 ± 2411 9854 ± 2664 < 0.001 8584 ± 2494 
Protein intake by FFQ, %en 17.4 ± 3.4 17.3 ± 3.2 17.1 ± 3.0 16.7 ± 2.9 15.5 ± 2.7 < 0.001 16.9 ± 3.2 
Fat intake by FFQ, %en 32.8 ± 6.7 33.8 ± 6.2 34.3 ± 6.1 34.7 ± 5.7 35.8 ± 5.4 < 0.001 34.3 ± 6.1 
Carbohydrate intake by FFQ, %en 47.8 ± 7.0 47.3 ± 6.3 47.3 ± 6.1 47.8 ± 5.7 48.0 ± 5.5 < 0.001 47.7 ± 6.2 
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Alcohol intake by FFQ, %en 3.3 ± 5.3 3.4 ± 4.7 3.1 ± 4.2 2.7 ± 3.6 2.5 ± 3.5 < 0.001 3.0 ± 4.3 
Alcohol intake by HLQ, units/week 3 (1-10) 4 (2-11) 4 (2-10) 4 (1-9) 4 (1-10) < 0.001 4 (1-10) 
Data are presented as mean ± standard deviation, percentage (number) or median (interquartile range). Differences between groups were analysed by ANOVA 2 
for continuous variables, and by Chi-square test for categorical variables. Continuous variables with a skewed distribution (triglycerides, C-reactive protein, 3 
alcohol intake) were analyzed by Kruskal-Wallis test. 4 
* These variables have missing data: Nwaist/hip ratio= 20,928; NApoAI=16,035; NApoB=16022; NCRP=16,162. 5 
6 
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Table 2: Risk of total (fatal and non-fatal) and fatal cardiovascular disease incidence by quintiles of chocolate intake in EPIC-Norfolk 7 
(1993-2008). 8 
 
Range (g/d) 
Total 
Quintile 1 
0 
Quintile 2 
0.6-3.5 
Quintile 3 
4.1-7.0 
Quintile 4 
7.2-15.5 
Quintile 5 
15.6-98.8 
P linearity 
Total CVD/n (%) 3013/20,951 (14.4) 729/4195 (17.4) 693/4437 (15.6) 528/4035 (13.1) 563/4106 (13.7) 500/4178 (12.0)  
Model 1  1.00 0.94 (0.85-1.05) 0.94 (0.84-1.05) 0.87 (0.78-0.98) 0.84 (0.75-0.94) 0.001 
Model 2  1.00 0.98 (0.88-1.08) 0.97 (0.87-1.09) 0.90 (0.80-1.00) 0.86 (0.76-0.97) 0.006 
Model 3  1.00 0.99 (0.89-1.10) 0.99 (0.88-1.10) 0.91 (0.81-1.02) 0.89 (0.79-1.00) 0.018 
 2207/16,162 (13.7) 548/3251 (16.9) 512/3406 (15.0) 375/3102 (12.1) 422/3220 (13.1) 350/3183 (11.0)  
Model 4a  1.00 1.00 (0.89-1.13) 0.96 (0.84-1.09) 0.90 (0.79-1.03) 0.82 (0.72-0.95) 0.003 
Model 4b  1.00 1.00 (0.88-1.12) 0.95 (0.83-1.09) 0.90 (0.79-1.02) 0.82 (0.71-0.95) 0.003 
Fatal CVD/n (%) 1107/20,951 (5.3) 308/4195 (7.3) 238/4437 (5.4) 193/4035 (4.8) 206/4106 (5.0) 162/4178 (3.9)  
Model 1  1.00 0.77 (0.65-0.92) 0.90 (0.75-1.07) 0.78 (0.66-0.94) 0.71 (0.59-0.86) 0.001 
Model 2  1.00 0.80 (0.68-0.95) 0.94 (0.79-1.13) 0.81 (0.67-0.97) 0.73 (0.60-0.89) 0.005 
Model 3  1.00 0.82 (0.69-0.98) 0.96 (0.80-1.15) 0.82 (0.68-0.98) 0.75 (0.62-0.92) 0.011 
 805/16,162 (5.0) 231/3251 (7.1) 174/3406 (5.1) 133/3102 (4.3) 154/3220 (4.8) 113/3183 (3.6)  
Model 4a  1.00 0.82 (0.67-1.00) 0.91 (0.73-1.13) 0.81 (0.66-1.00) 0.71 (0.56-0.89) 0.008 
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Model 4b  1.00 0.81 (0.66-0.99) 0.90 (0.73-1.12) 0.80 (0.65-0.99) 0.70 (0.55-0.89) 0.008 
Model 1 adjusted for sex and age. 9 
Model 2 adjusted for sex, age, smoking, physical activity, energy intake and alcohol consumption. 10 
Model 3: as model 2 and diabetes, body mass index, systolic blood pressure, LDL-cholesterol and HDL-cholesterol.  11 
Model 4a: as model 3, but restricted to number of participants for whom CRP is available (N=16,162). 12 
Model 4b: as model 3 and C-reactive protein (N=16,162). 13 
14 
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Table 3: Risk of total (fatal and non-fatal) coronary heart disease and stroke incidence by quintiles of chocolate intake in EPIC-Norfolk 15 
(1993-2008). 16 
 
Range (g/d) 
Total 
Quintile 1 
0 
Quintile 2 
0.6-3.5 
Quintile 3 
4.1-7.0 
Quintile 4 
7.2-15.5 
Quintile 5 
15.6-98.8 
P linearity 
CHD/n (%) 2434/20,951 (11.6) 577/4195 (13.8) 564/4437 (12.7) 437/4035 (10.8) 449/4106 (10.9) 407/4178 (9.7)   
model 1  1.00 0.97 (0.86-1.09) 0.97 (0.86-1.10) 0.87 (0.77-0.99) 0.85 (0.75-0.96) 0.003 
model 2  1.00 1.01 (0.90-1.13) 1.01 (0.89-1.15) 0.91 (0.80-1.03) 0.88 (0.77-1.01) 0.024 
model 3  1.00 1.03 (0.91-1.15) 1.03 (0.91-1.17) 0.92 (0.81-1.05) 0.91 (0.80-1.04) 0.06 
 1754/16,162 (10.9) 435/3251 (13.4) 407/3406 (11.9) 307/3102 (9.9) 325/3220 (10.1) 280/3183 (8.8)  
model 4a  1.00 1.00 (0.87- 1.15) 0.98 (0.85- 1.14) 0.88 (0.76- 1.01) 0.83 (0.71- 0.97) 0.006 
model 4b  1.00 1.00 (0.87- 1.14) 0.98 (0.84- 1.13) 0.87 (0.75- 1.01) 0.82 (0.70- 0.97) 0.005 
Stroke/n (%) 848/20,951 (4.0) 226/4195 (5.4) 187/4437 (4.2) 139/4035 (3.4) 165/4106 (4.0) 131/4178 (3.1)   
model 1  1.00 0.83 (0.68-1.00) 0.84 (0.68-1.04) 0.85 (0.70-1.04) 0.77 (0.62-0.96) 0.036 
model 2  1.00 0.85 (0.70-1.03) 0.87 (0.70-1.07) 0.86 (0.70-1.06) 0.77 (0.62-0.97) 0.046 
model 3  1.00 0.86 (0.71-1.05) 0.87 (0.71-1.08) 0.88 (0.71-1.07) 0.78 (0.63-0.98) 0.06 
 648/16,162 (4.0) 168/3251 (5.2) 149/3406 (4.4) 100/3102 (3.2) 132/3220 (4.1) 99/3183 (3.1)  
model 4a  1.00 0.95 (0.76-1.18) 0.87 (0.67-1.12) 0.94 (0.74-1.18) 0.81 (0.62-1.05) 0.14 
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model 4b  1.00 0.95 (0.76-1.18) 0.87 (0.67-1.11) 0.94 (0.74-1.18) 0.80 (0.62-1.05) 0.14 
Model 1 adjusted for sex and age. 17 
Model 2 adjusted for sex, age, smoking, physical activity, energy intake and alcohol consumption. 18 
Model 3: as model 2 and diabetes, body mass index, systolic blood pressure, LDL-cholesterol and HDL-cholesterol.  19 
Model 4a: as model 3, but restricted to number of participants for whom CRP is available (N=16,162). 20 
Model 4b: as model 3 and C-reactive protein (N=16,162). 21 
 22 
 23 
24 
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Table 4: Study design, participants, follow up and outcomes for studies evaluating chocolate consumption and cardiovascular disease. 25 
Study 
ID 
Dietary 
exposures 
Study design No in 
analysis 
Characteristics Follow-
up 
(years) 
Outcome measures Measures of association 
Buijsse 
2006 
Cocoa intake Prospective Cohort, 
Netherlands 
470 White men with mean 
age 72 years. 
15 Cardiovascular 
mortality at 15 years 
Relative risk: 0.50 (0.32-0.78) for 
>2.25g/day vs. <0.5 g/day. (top vs. 
bottom tertile) 
Buijsse 
2010 
Chocolate 
consumption 
Prospective Cohort, 
Potsdam, Germany 
19357 Men and women with 
mean age of 49 years, 
38% were men and no 
history of myocardial 
infarction and stroke and 
not using blood pressure 
drugs. 
10 Incident Myocardial 
infarction, stroke and 
composite of both at 
mean of 8.1 years 
follow-up 
Relative risk: myocardial infarction 
0.73 (0.47-1.18), stroke 0.52 (0.30-
0.89), composite 0.61 (0.44-0.87) for 
4th quartile vs. 1st quartile energy-
adjusted chocolate consumption. 
Djousse 
2011 
Chocolate 
consumption 
Cross-sectional, United 
States 
4970 Men and women with 
mean age of 52 years 
(range 25-93 years), 45% 
were men and 5% were 
of African-American 
origin.  
NA Prevalent Coronary 
heart disease 
(myocardial infarction 
or coronary 
revascularization) 
Odds ratio: 0.43 (0.27-0.68) for >5 
times a week vs. no consumption. 
(based on some degree of post-hoc 
categorization of collected data) 
Janszky 
2009 
Chocolate 
consumption 
Prospective Cohort. 
Sweden 
1169 Men (71%) and women 
who survived an acute 
myocardial infarction 
with mean age of 59 
years. 
8 Cardiovascular 
mortality, recurrent 
myocardial infarction, 
stroke and congestive 
heart failure 
Hazard ratio: CV mortality 0.34 (0.17-
0.70), recurrent MI 0.86 (0.54-1.37), 
stroke 0.62 (0.33-1.16) for <2X week 
vs. never. (based on some degree of 
post-hoc categorization of collected 
data) 
Larsson 
2011 
Chocolate 
consumption 
Prospective Cohort, 
Sweden 
33372 Women with no history 
of stroke, age range 49-
83 years. 
10.4 Incident Stroke Relative risk: 0.80 (0.66-0.99) >45 
g/week vs. <8.9 g/week. (top vs. 
bottom quartile)  
Larsson 
2012 
Chocolate 
consumption 
Prospective Cohort, 
Sweden 
37103 Men with mean age mean 
of 59 years and no 
history of stroke. 
10.2 Incident Stroke Relative risk: 0.83 (0.70-0.99) for 
>51.6 g/week vs. <12 g/week (top vs. 
bottom quartile) 
Lewis 
2010 
Chocolate 
consumption 
Post-hoc analysis of a 
randomized trial of 
calcium supplementation 
in women, Australia 
1216 Women, mean age 75 
years 
9.5 Atherosclerotic 
vascular disease and 
ischemic heart disease 
Hazard ratio: Ischemic heart disease 
0.65 (0.46-0.94) for <1 serving/week 
vs. 
>1 serving/week (based on some 
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Study 
ID 
Dietary 
exposures 
Study design No in 
analysis 
Characteristics Follow-
up 
(years) 
Outcome measures Measures of association 
degree of post-hoc categorization of 
collected data) 
Mink 
2007 
Chocolate 
consumption 
Prospective Cohort, 
USA. 
34489 Women with mean age 
62 years with no history 
of heart disease. 
16 Coronary heart disease 
mortality and stroke 
mortality 
Rate ratio: CHD mortality 0.98 (0.88-
1.10), stroke mortality 0.85 (0.70-1.03) 
for <1 per week vs. > 1 per week 
(based on some degree of post-hoc 
categorization of collected data) 
Current 
study 
Chocolate 
consumption 
Cohort 25663 55% women. 99.6% 
white Caucasians), mean 
age 59 years with no 
history of heart disease or 
stroke. 
11.8 Incident coronary heart 
disease, stroke and 
composite of the two, 
defined as 
cardiovascular disease. 
Hazard ratio: CHD 0.88 (0.77-1.01), 
stroke 0.77 (0.62-0.96), CVD 0.86 
(0.76-0.97).(top quintile vs. bottom 
quintile) 
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Supplementary Figure 1: Love plot examining the standardized difference in covariates 
before and after propensity score adjustment. 
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Supplementary Figure 2: Search results and study selection for meta-analysis of 
chocolate consumption and risk of cardiovascular disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
392 results from search of 
MEDLINE and EMBASE. 369 
results search of from Web of 
Science. 
 
615 were screened based on 
title/abstract. 
 
146 duplicate articles were 
removed. 
 
10 potentially relevant articles were 
found and 5 reviews were checked 
for additional studies. 
605 articles were not 
relevant. 
 
8 papers were in final inclusion 
after searching bibliographies of 
reviews (1 additional paper). 
8 papers were excluded: 2 were 
editorial/comments, 1 evaluated heart failure, 
1 evaluated calcified aortic plaques, 1 had no 
cardiovascular outcomes and 3 did not 
evaluate chocolate. 
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Supplementary Table 1:   Baseline cardiovascular risk factors by quintiles of chocolate intake in 20,951 men and women of EPIC-
Norfolk with 8,373 matched and unmatched on the propensity score (quintile 1 vs quintile 5), mean (sd) or percentage 
 Unmatched Matched 
 Quintile 1 Quintile 5 p-value Quintile 1 Quintile 5 p-value 
Age 60.71(9.00) 57.07(9.39) <0.001 58.64(8.91) 58.98(9.40) 0.19 
Body mass index 26.34(4.05) 25.96(3.70) <0.001 26.00(4.03) 26.00(3.63) 0.95 
C-reactive protein 3.01(5.84) 2.91(7.45) 0.55 2.85(4.99) 3.03(8.10) 0.41 
Diabetes mellitus (%) 7.31% 0.26% <0.001 1.14% 1.25% <0.001 
Alcohol intake by HLQ 7.08(10.13) 6.99(9.14) 0.67 7.07(9.46) 6.91(9.00) 0.54 
Carbohydrate intake by FFQ 231.78(76.06) 295.71(87.60) <0.001 259.56(76.58) 257.01(64.72) 0.20 
Protein intake by FFQ 78.88(20.89) 88.14(22.05) <0.001 85.63(20.96) 79.74(18.14) <0.001 
Fat intake by FFQ 66.31(26.83) 91.43(31.29) <0.001 76.36(27.32) 77.51(23.76) 0.11 
HDL-cholesterol 1.43(0.43) 1.40(0.41) <0.001 1.44(0.44) 1.42(0.41) 0.11 
LDL-cholesterol 3.97(1.04) 3.94(1.02) 0.29 3.89(1.01) 4.00(1.03) <0.001 
Physical activity - Moderately 
inactive 
26.76% 27.51% 0.53 28.41% 28.84% 0.80 
Physical activity - Moderately 
active 
20.60% 24.48% 0.006 23.30% 24.06% 0.79 
Physical activity - Active 16.91% 21.65% 0.006 19.39% 18.74% 1.00 
Sex (% men) 44.9% 52.1% 0.001 43.2% 42.5% 0.98 
Smoking status (% current) 9.47% 14.1% <0.001 11.8% 11.6% 0.93 
Systolic blood pressure 136.75(18.61) 133.66(17.14) <0.001 135.13(17.79) 134.61(17.65) 0.29 
a propensity score based on the covariates used in Model 2: age, sex, smoking status,  physical activity, FFQ energy and HLQ alcohol  
b for comparison of characteristics before and after matching, derived by t-test 
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Supplementary Table 2: Hazard ratios of coronary heart disease, stroke and cerebrovascular disease (all and fatal)  by quintiles of cocoa 
intake in 20,951 men and women of EPIC-Norfolk using propensity score analyses  
 Quintile 1 vs 5   
 Events/N Hazard ratio  
(95% CI) 
   
CHD (fatal and non-fatal)      
   Model 1 577/3618 vs 407/3771 0.85 (0.75-0.97)     
   Model 2 577/3618 vs 407/3771  0.88 (0.77-1.00)   
   Model 3 577/3618 vs 407/3771  0.91 (0.80-1.04)     
  Model 4a 435/2816 vs 280/2903  0.83 (0.71-0.97)   
  Model 4b 435/2816 vs 280/2903 0.82 (0.70-0.97)   
   Propensity score adjusted 435/2816 vs 280/2903 0.88 (0.76-1.01)   
Matched by propensity score 307/2273 vs 283/2297 0.91 (0.77-1.07)    
Stroke (fatal and non-fatal)      
   Model 1 226/3969 vs 131/4047 0.78 (0.63-0.96)    
   Model 2 226/3969 vs 131/4047 0.78 (0.62-0.98)     
   Model 3 226/3969 vs 131/4047  0.80 (0.64-1.00)   
   Model 4a 168/3083 vs 99/3084 0.81 (0.63-1.05)   
   Model 4b 168/3083 vs 99/3084 0.81 (0.63-1.06)   
   Propensity score adjusted 168/3083 vs 99/3084 0.78 (0.62-0.99)    
Matched by propensity score 125/2455 vs 94/2486 0.75 (0.57-0.99)    
 CVD (fatal and non-fatal)     
   Model 1 729/3466 vs 500/3678 0.84(0.75-0.94)   
   Model 2 729/3466 vs 500/3678  0.86(0.76-0.97)   
   Model 3 729/3466 vs 500/3678 0.89(0.79-1.00)   
  Model 4a 548/2703 vs 350/2833 0.82(0.72-0.95)   
  Model 4b 548/2703 vs 350/2833 0.82(0.71-0.95)   
   Propensity score adjusted 548/2703 vs 350/2833 0.86(0.75-0.97)   
Matched by propensity score 397/2183 vs 348/2232 0.87(0.75-1.00)   
 CVD (fatal)     
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   Model 1 308/3887 vs 162/4016 0.73(0.60-0.89)   
   Model 2 308/3887 vs 162/4016 0.76(0.62-0.92)   
   Model 3 308/3887 vs 162/4016 0.79(0.65-0.97)   
  Model 4a 231/3020 vs 113/3070 0.73(0.57-0.92)   
  Model 4b 231/3020 vs 113/3070 0.72(0.57-0.91)   
   Propensity score adjusted 231/3020 vs 113/3070 0.81(0.65-1.00)   
Matched by propensity score 160/2420 vs 118/2462 0.77(0.60-0.97)   
     
Model 1 adjusted for sex and age. 
Model 2 adjusted for sex, age, smoking, physical activity, energy intake and alcohol consumption. 
Model 3: as model 2 and diabetes, body mass index, systolic blood pressure, LDL-cholesterol and HDL-cholesterol.  
Model 4a: as model 3, but restricted to number of participants for whom C-reactive protein is available. 
Model 4b: as model 3 and C-reactive protein.  
 
a Propensity scores are based on the covariates included in Model 2  
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Supplementary Table 3: Quality assessment of studies which evaluated chocolate consumption and cardiovascular disease. 
Study 
ID 
Ascertaining Chocolate Consumption Determining Cardiovascular Outcome Adjustment for Confounders 
Buijsse 
2006 
The habitual dietary intake of the subjects was determined by 
interview conducted by experienced dieticians (using a cross-
check dietary history method adapted to the Dutch situation). 
A total of 24 cocoa-containing foods and the intake of cocoa 
from individual foods was summed to yield actual cocoa in 
grams per day for each subject. 
Information on the cause of death was obtained from 
hospital discharge data, general practitioners, and 
Statistics Netherlands.  The final causes of death were 
ascertained by one clinical epidemiologist and coded 
according to the ICD-9. 
Age; body mass index; smoking status; alcohol consumption; 
physical activity; aspirin use; anticoagulant use; diet prescription 
(Y/N); consumption of: vegetables, fruit, low and medium fat dairy, 
meat, sugar confectionery other than chocolate, cookies, savoury 
foods, nuts, and coffee; and total calorie intake 
Buijsse 
2010 
Usual food intake in the year before baseline was assessed by 
a self administered 148-item food-frequency questionnaire.  
Chocolate consumption was asked by how frequent a 
chocolate bar of 50 g was consumed. Participants could 
indicate whether they consumed half, one, two, or three bars 
of chocolate. 
Possible cases of MI or stroke were identified by self-
reports or death certificates. Self-reported information 
was obtained by at least one of the four follow-up 
questionnaires, which contained questions about 
physician-diagnosed CVD and the use of medication. 
All possible cases were verified by reviewing medical 
records from the hospital, by contacting the patients’ 
physician, or by review of the death certificate. 
Age, sex, alcohol intake, employment status, body mass index, waist 
circumference, smoking status, occupational physical activity, sports 
cycling, education, and total energy intake 
Djousse 
2011 
Dietary information collected through a staff-administered 
semi-quantitative food frequency questionnaire.  Each subject 
was asked the following question: “In the past year, how often 
on average did you consume chocolate bars or pieces, such as 
Hershey’s Plain, M & M, Snickers, Reeses; 1 ounce?”. 
Possible answers were: “>6 per day, 4-6 per day, 2-3 per day, 
1 per day, 5-6 per week, 2-4 per week, 1 per week, 1-3 per 
month, and almost never”. 
Prevalent CHD was assessed from the medical history 
and a 12-lead electrocardiogram. Individuals were 
defined as a case of CHD if there was a self-reported 
history of myocardial infarction, percutaneous 
transluminal coronary angioplasty, or coronary artery 
bypass graft that could be validated by review of 
medical records, or if abnormal Q waves detected on 
a resting 12-lead electrocardiogram. 
Age, sex, dietary linoleic acid intake, education, exercise, smoking 
status, alcohol intake, fruit and vegetables intake, energy intake, non-
chocolate candy intake   
Janszky 
2009 
Questionnaire distributed few days after AMI regarding the 
number of usual (50 g) portions of chocolate that participants 
usually consumed per day, per week or per month during the 
last 12 months. The original consumption categories included: 
never, less than once per month, 1–3 times per month, once 
per week, twice per week, 3–4 times per week, 5–6 times per 
week, once per day, twice per day and 3 times or more per 
day. 
All-cause and cardiac mortality (ICD-9 and -10) were 
used as primary end-points as provided by the 
National Cause of-death Register. Patients were also 
followed for nonfatal AMI using the Swedish 
Myocardial Infarction Register. Information on 
hospitalization for stroke was derived from the 
Swedish Hospital Discharge Register. 
Age, sex, smoking status, obesity, physical inactivity, alcohol 
consumption (g/day), filtered coffee intake (cups/day), educational 
attainment, sweet score 
Larsson 
2011 
Validated self-administered food-frequency questionnaire 
regarding how often on average they had consumed chocolate 
and 95 other foods during the previous year. There were 8 
pre-defined consumption categories ranging from never to ≥3 
times a day. 
Incident cases of first stroke were ascertained by 
linkage with the Swedish Hospital Discharge 
Registry. The stroke events were classified by ICD-10 
code. Information on dates of death was obtained 
from the Swedish Cause of Death Registry. 
Age, education (less than high school, high school, or university), 
smoking status and pack-years of smoking (never; past <20, 20 to 
39, or ≥40 pack-years; or current <20, 20 to 39, or ≥40 pack-years), 
body mass index (<20, 20 to 24.9, 25 to 29.9, or ≥30 kg/m2), total 
physical activity (metabolic equivalent of energy expenditure 
hours/day, quartiles), aspirin use (never, 1 to 6, ≥7 tablets/week), 
self-reported history of hypertension (yes or no), diagnosis of atrial 
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fibrillation (yes or no), family history of myocardial infarction before 
60 years of age (yes or no), and intakes of total energy (kcal/day), 
alcohol (non-drinkers or <3.4, 3.4 to 9.9, or ≥10.0 g/day), coffee (<1, 
1 to 2, 3 to 4, or ≥5 cups/day), tea (0, <1, 1 to 1.9, 2 to 3.9, ≥4 
cups/day), and quartiles (g/day) of fresh red meat, processed red 
meat, fish, fruits, and vegetables. 
Larsson 
2012 
Validated self-administered food-frequency questionnaire that 
included 96 foods and beverages. Participants reported how 
often on average they had consumed chocolate based on 8 
pre-specified consumption categories, ranging from never to 3 
or more times per day. 
Incident cases of first stroke were identified by 
linkage of the study population to the Swedish 
Hospital Discharge Registry and ICD-10 codes were 
used to identify stroke events in the cohort. 
Information on dates of death was obtained from the 
Swedish Death Register. 
Age, education, smoking status, and pack-years of smoking, body 
mass index, total physical activity, aspirin use, history of 
hypertension, atrial fibrillation, family history of myocardial 
infarction, and intakes of total energy, alcohol, coffee, tea, fresh red 
meat, processed meat, fish, fruits, and vegetables. 
Lewis 
2010 
At baseline, information on food and beverage consumption 
frequency was verified by their general practitioner and 
previously validated questionnaires. The frequency of 
chocolate consumption was collapsed into the following 3 
categories: less than 1 serving/wk (rarely), 1 to 6 servings/wk 
(weekly), and 7 or more servings/wk (daily).  
The Western Australian Data Linkage System 
(WADLS) was used to assess clinical outcomes. 
Atherosclerotic vascular disease events were defined 
using diagnosis codes from the ICD-10-AM. 
Age, body mass index, socioeconomic status, and energy intake at 
baseline. 
Mink 
2007 
Dietary assessment was performed using a 127-item food-
frequency questionnaire was adapted from the questionnaire 
used in the 1984 Nurses’ Health Study survey which had 
detailed information on fruit (15 items) and vegetables (29 
items) and included information on individual foods with high 
flavonoid content (eg, chocolate). 
Women were followed annually through the State 
Health Registry of Iowa and identified through the 4 
follow-up questionnaires by linking women who did 
not respond to the questionnaire with the National 
Death Index. The ICD-9 was used to classify the 
reported cause of death. 
Age, energy consumption, marital status, education, blood pressure, 
diabetes, body mass index, waist to hip ratio, physical activity, 
smoking, oestrogen use 
Current 
study 
Three questions from a food frequency questionnaire were 
considered indicative of chocolate consumption namely 
"Chocolates singles or squares" (average portion size of 8 g), 
"Chocolate snack bars, e.g. Mars, Crunchie" (average portion 
size of 50 g) and "Cocoa, hot chocolate (cup)" (average 
portion size of 12 g powder weight). Frequency categories 
were multiplied by the portion size to derive the amount of 
chocolate products eaten (g/day). The sum of the weights of 
these food items consumed, rather than their flavonoid or 
cocoa content, formed the measure of exposure. 
Patients admitted to hospital were identified using 
their National Health Service number by data linkage 
with ENCORE.  All participants were flagged for 
death certification at the UK Office of National 
Statistics, ascertaining vital status for the entire 
cohort.  Diagnosis of CHD, stroke and CVD 
(combination of CHD and stroke) was based on ICD-
10 codes. 
Age, sex, smoking status, body mass index, systolic blood pressure, 
LDL-cholesterol, HDL-cholesterol, C-reactive protein, physical 
activity, protein intake, total fat intake, total carbohydrate intake and 
alcohol intake. 
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Supplementary Table 4: Use of adjustments or exclusions in studies which evaluated 
chocolate consumption and cardiovascular disease. 
Study ID  Diabetes 
mellitus  
Body Mass 
Index  
Total Energy 
Intake  
Smoking  Blood Pressure  Cholesterol  
Buijsse 
2006 
Y (excluded 
patients with 
diabetes) 
Y Y Y N N 
Buijsse 
2010 
Y Y Y Y N N 
Djousse 
2011 
Y N Y Y N N 
Janszky 
2009 
Y (excluded 
patients with 
diabetes) 
N N Y N N 
Larsson 
2011 
Y (excluded 
patients with 
diabetes) 
Y Y Y N N 
Larsson 
2012 
Y (excluded 
patients with 
diabetes) 
Y Y Y Y 
(hypertension) 
N 
Lewis 2010 N Y Y N N N 
Mink 2007 Y Y Y Y Y N 
Current 
study 
Y Y Y Y Y (systolic 
blood pressure)* 
Y* 
*Although these factors were included in the study, the model without these risk factors were 
included in the meta-analysis. 
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Data Supplement 1: Search strategy for chocolate consumption and risk of cardiovascular 
disease 
 
EMBASE,MEDLINE; Duplicate filtered: [((cacao OR chocolate OR cocoa) AND 
((cardiovascular disease) OR (coronary heart disease) OR (ischaemic heart disease) OR 
(ischemic heart disease) OR stroke OR (brain vascular accident) OR (cerebrovascular 
accident) OR (cerebral vascular accident))).ti,ab]; 392 results. 
